News
Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...
It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition ...
Molecular and clonal evolution of primary lesions vs brain metastasis of EGFR-mutated NSCLC: A retrospective cohort study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback